title: Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
abstract: The role of total body irradiation (TBI) for allogeneic bone marrow transplantation (BMT) for acute leukemia in first complete remission was reevaluated in this study. From Japanese BMT Registry, data of 123 acute leukemia patients in first complete remission who underwent allogeneic bone marrow transplantation in 22 hospitals between 1988 and 1990 were available for the present comparative study of preparation regimens with or without total body irradiation. Two-year survivals were 77% and 51% in the TBI containing regimen group and in the non-TBI regimen group, respectively (p = 0.0010). Corresponding two-year relapse rates were 16% and 37%, respectively (p = 0.0197). Corresponding probabilities of developing interstitial pneumonitis were 21% and 24%, respectively (p = 0.8127). The analysis of causes of death indicated that non-TBI regimen increased the incidence of septicemia and lethal organ failures, such as liver, heart, lung and other multiple sites. It was emphasized that an additional role of total body irradiation was to disperse the treatment-related toxicity in allogeneic bone marrow transplantation for acute leukemia.
authors: Department of Radiation Oncology, Osaka University Medical School, Japan.
authors: T
authors: T
authors: Inoue
authors: H
authors: H
authors: Ikeda
authors: H
authors: H
authors: Yamazaki
authors: J T
authors: JT
authors: Tang
authors: C
authors: C
authors: Song
authors: T
authors: T
authors: Teshima
authors: S
authors: S
authors: Murayama
authors: M
authors: M
authors: Ohtani
authors: H
authors: H
authors: Shibata
authors: T
authors: T
authors: Masaoka
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007564:Japan; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D015376:Nimustine / Q000008:administration & dosage; D016016:Proportional Hazards Models; D011879:Radiotherapy Dosage; D012074:Remission Induction; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
chemical_list: D003561:Cytarabine; D015376:Nimustine; D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan; D008727:Methotrexate